Lucid Diagnostics (LUCD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual meeting scheduled for June 24, 2026, to be held virtually at 11:00 a.m. Eastern time.
Stockholders can vote electronically using a 12-digit control number.
Proxy materials, including the annual report and proxy statement, are available online for review.
Voting matters and shareholder proposals
Election of three Class B directors to serve until the third succeeding annual meeting.
Proposal to amend the certificate of incorporation to increase authorized common stock by 100,000,000 shares, from 300,000,000 to 400,000,000.
Ratification of CBIZ CPAS P.C. as independent registered public accounting firm for the year ending December 31, 2026.
Board recommends voting "FOR" all management proposals.
Board of directors and corporate governance
Three board seats (Class B) are up for election, with terms lasting until the third succeeding annual meeting.
Latest events from Lucid Diagnostics
- Q2 2026 revenue hit $1.5M with expanded coverage, but losses and cash burn persist.LUCD
Q2 2026 - Non-invasive test for Barrett's Esophagus nears Medicare coverage, poised for rapid U.S. growth.LUCD
Canaccord Genuity's 46th Annual Growth Conference - All proposals passed, including director elections and share authorization increase.LUCD
AGM 2026 - Breakthrough esophageal precancer screening drives growth, adoption, and reimbursement progress.LUCD
Investor presentation - Q1 2026 revenue hit $1.3M on 3,177 tests, with cash runway extended and Medicare approval pending.LUCD
Q1 2026 - Shareholders will vote on director elections, capital increase, and auditor ratification, with board support.LUCD
Proxy filing - Shareholders will vote on director elections, capital increase, and auditor ratification under strong governance.LUCD
Proxy filing - Breakthrough non-endoscopic screening drives early esophageal cancer detection in a $60B market.LUCD
Company presentation - Q3 revenue up 20% to $1.2M, record test growth, Medicare submission, but funding risks persist.LUCD
Q3 2024